Site Selection and Assessment

Our multifaceted approach to site identification and selection is tailored to each study protocol to ensure the best-fit sites with the most appropriate capabilities and population.

investing in research-ready sites

Our relationships with sites are built on our shared investment in their sustainability, helping sites develop and maintain research capacity so they are research-ready as soon as there is a need. Ultimately, this increased research capacity will help address public health issues around the globe.

Benefits of Collaboration

scalable, global site selection

Using a combination of our established relationships and analytics on our extensive database of high-quality, research-ready sites, the FHI Clinical team helps select the sites that are the best fit for your protocol(s).

Established Relationships

We rely on our established network of ~2,800 sites in nearly 75 countries worldwide that have the required infrastructure and community engagement capabilities to help locate, recruit and retain patients for observational and epidemiological studies and across all clinical trial phases, from Phase 1 to Phase 4.


Would your site like to participate in FHI Clinical's studies?

Provide your site information to be evaluated as a potential partner. 

Our Involvement in Research Networks

Top 9 Indications Supported by Our Database of Sites

Of the sites in our database:

~ 0 %
of sites have 6+ years of experience
~ 0 %
of sites have vaccine clinical trial experience
~ 0 %
of those sites have 7+ years of vaccine clinical trial experience

Competitive Intelligence and Analytics

Using our proprietary database of thousands of established, high-quality sites, our Global Strategy team analyzes their capabilities and populations served against your protocol requirements. This feasibility assessment continues throughout the study to ensure successful performance.

comprehensive, customized site assessment

Site feasibility assessments ensure that the “ideal sites” are identified for a specific protocol. To achieve this, we’ve developed assessment strategies and tools based on industry best practices, input from our team of Scientific Advisory Experts and our experience with sites that successfully contribute to studies.

Our site feasibility assessments incorporate the following:


Based on our experience in crisis-response settings, we’ve developed a key set of activities and resources that enable us to meet compressed trial start-up timelines.

Case Study: Site Feasibility

Case Study: Site and Investigator Selection

Learn more about our specific experience through our case studies:

Case Study

Phase II Trial of a Chikungunya Vaccine in the Caribbean

The study team maintained a 91% retention rate in a study of a Chikungunya virus (CHIKV) vaccine, despite study disruptions due to natural disasters, including Hurricane Maria, and political unrest near the sites in five Caribbean countries in a CHIKV endemic region.
Case Study

Rapid Site Assessment and Recommendations for Clinical Trials of a New Malaria Treatment

Targeted geographic areas for the development of an antimalarial drug by Novartis included malaria-endemic regions in Africa and Asia, and Novartis requested assistance identifying and assessing potential clinical sites for their planned clinical trial. Our team conducted 38 rapid, in-depth, 2.5-day site feasibility assessments in the 18 countries.
Case Study

Rescue of an Ongoing Global, Multi-Site Oncology Trial

In a Phase 3 study with a lengthy intervention for colorectal cancer, the project team reached a 70% retention rate, with steadily increasing enrollment rates, by implementing strategies to address poor patient enrollment and retention.